TEVA – teva pharmaceutical industries limited american depositary shares (US:NASDAQ)
Stock Stats
News
Teva Pharmaceutical Industries (NYSE:TEVA) had its price target raised by analysts at Piper Sandler from $30.00 to $40.00. They now have an "overweight" rating on the stock.
Teva Pharmaceutical Industries' (NYSE:TEVA) investors will be pleased with their impressive 228% return over the last three years [Yahoo! Finance]
Teva Pharmaceutical Industries (NYSE:TEVA) had its price target raised by analysts at The Goldman Sachs Group, Inc. from $31.00 to $35.00. They now have a "buy" rating on the stock.
Alvotech and Teva Secure U.S. Settlement Date for AVT06, a Proposed Biosimilar to Eylea®
Teva Pharmaceutical Industries (NYSE:TEVA) had its price target raised by analysts at JPMorgan Chase & Co. from $28.00 to $35.00. They now have an "overweight" rating on the stock.
Form 4 TEVA PHARMACEUTICAL INDU For: Dec 16 Filed by: Weiss Amir
Form 4 TEVA PHARMACEUTICAL INDU For: Dec 16 Filed by: MIGNONE ROBERTO
Form 144 TEVA PHARMACEUTICAL INDU Filed by: BRIDGER MANAGEMENT, LLC
Form 8-K TEVA PHARMACEUTICAL INDU For: Dec 10
Form 4 TEVA PHARMACEUTICAL INDU For: Dec 09 Filed by: Daniell Richard
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.